Waterloo, Iowa Clinical Trials

A listing of Waterloo, Iowa clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, …

major surgery
cancer treatment
irinotecan
metastasis
bevacizumab
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 65 views
  • 16 Feb, 2021
  • +912 other locations
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. …

cancer treatment
insulin
systemic chemotherapy
chronic hepatitis b
cardiac disease
MercyOne Waterloo Medical Center
 (2.7 away) Contact site
  • 206 views
  • 28 Feb, 2021
  • +794 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

hormone therapy
growth factor
cyclophosphamide
cancer treatment
core needle biopsy
MercyOne Waterloo Cancer Center ( Site 0016)
 (1.5 away) Contact site
  • 188 views
  • 28 Feb, 2021
  • +278 other locations
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclonal antibody that may interfere with the …

hormone therapy
thrombocytopenia
lymphadenopathy
night sweats
anemia
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 624 views
  • 28 Feb, 2021
  • +727 other locations
Dissemination of the Cardiovascular Risk Service

The objective of this study is to evaluate the implementation of of a remote, pharmacist-led cardiovascular risk service (CVRS) in 12 large, organizationally and culturally diverse hospitals and health-systems, many with high proportions of minority and underserved patients.

systolic blood pressure
hypertension
diabetes
Northeast Iowa Family Practice Center
 (1.5 away) Contact site
  • 67 views
  • 25 Jan, 2021
  • +13 other locations
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to …

lung carcinoma
cancer treatment
metastasis
liver metastases
anamorelin hydrochloride
MercyOne Waterloo Cancer Center
 (1.5 away) Contact site
  • 197 views
  • 26 Jan, 2021
  • +72 other locations
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual …

MercyOne Waterloo Medical Center
 (2.7 away) Contact site
  • 139 views
  • 28 Feb, 2021
  • +468 other locations
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with …

diabetes
cyclophosphamide
vomiting
dexamethasone
metastasis
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 109 views
  • 18 Feb, 2021
  • +578 other locations
S0820 Adenoma and Second Primary Prevention Trial

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

adenoma
unstable angina
rectal carcinoma
aspirin
anticoagulants
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 2518 views
  • 28 Feb, 2021
  • +1023 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

diabetes
percutaneous coronary intervention
infarct
arterial disease
acute coronary syndrome
8400904 - Northeast Iowa Medical Education Foundation
 (1.5 away) Contact site
  • 1118 views
  • 27 Feb, 2021
  • +3414 other locations